Brensocatib is a once-daily oral DPP1 inhibitor marketed as BRINSUPRI for non-cystic fibrosis bronchiectasis. It is designed to reduce neutrophil-driven airway inflammation and has become the first approved treatment for this disease area in both the U.S. and EU according to the cited source. It is approved for patients aged 12 years and older.
Insmed reported total revenues of $606.4 million for 2025, with ARIKAYCE growing 19% annually. The FDA granted orphan drug designation to treprostinil palmitil for pulmonary arterial hypertension treatment in January 2026.
Drug Hunter's most-accessed resources, reviews, and case studies in 2025 reflected key trends in drug discovery, including the rise of oral macrocycles, advances in new modalities, and the shift from biologics to small molecules in immunology.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06685835 |
A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS) |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT06178783 |
A Study of the Palatability and Acceptability of Different Brensocatib Oral Liquid Formulations in Healthy Participants |
COMPLETED | PHASE1 |
| NCT06013241 |
A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) |
COMPLETED | PHASE2 |
| NCT05965570 |
A Study to Investigate Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy Participants |
COMPLETED | PHASE1 |
| NCT05826574 |
A Study to Assess Pharmacokinetics (PK) of Brensocatib Alone and With Multiple Doses of Rifampin or Esomeprozole in Healthy Participants |
COMPLETED | PHASE1 |
| NCT05673603 |
A Study of Brensocatib Following a Single Oral Administration in Participants With or Without Renal Impairment |
COMPLETED | PHASE1 |
| NCT05517525 |
A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Brensocatib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment |
COMPLETED | PHASE1 |
| NCT05355935 |
A Study to Investigate the Effects of Brensocatib on QT Interval in Healthy Participants |
COMPLETED | PHASE1 |
| NCT05344508 |
An Expanded Access Study to Assess Brensocatib for Participants With Non-Cystic Fibrosis Bronchiectasis |
APPROVED_FOR_MARKETING | |
| NCT05090904 |
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis |
COMPLETED | PHASE2 |
